A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease

Journal of Hepatology

Volumn 61, Issue 5, 2014, Pages 1073-1079

  Nischalke, Hans Dieter ^a   Lutz, Philipp ^a,g   Krämer, Benjamin ^a,g   Söhne, Jennifer ^a   Müller, Tobias ^b   Rosendahl, Jonas ^b   Fischer, Janett ^b   Berg, Thomas ^b   Hittatiya, Kanishka ^c   Fischer, Hans Peter ^c   Soyka, Michael ^d,e   Semmo, Nasser ^f   Nattermann, Jacob ^a,g   Sauerbruch, Tilman ^a   Strassburg, Christian P ^a,g   Stickel, Felix ^f   Spengler, Ulrich ^a,g  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d Psychiatric Hospital Meiringen   (Switzerland)

^e UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF BERN   (Switzerland)

^g German Center for Infection Research   (Germany)

Author keywords

Alcohol; HCC; Liver cirrhosis; NCAN; Neurocan; Polymorphism; Rs2228603; SNP

Indexed keywords

ALPHA FETOPROTEIN; NEUROCAN; LECTIN; MESSENGER RNA; NCAN PROTEIN, HUMAN; NERVE PROTEIN; PROTEOCHONDROITIN SULFATE;

ADULT; AGED; ALCOHOL ABUSE; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALLELE; ARTICLE; CANCER RISK; CANCER SIZE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; LIVER CELL; LIVER CELL CARCINOMA; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; ALCOHOLISM; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; CELL LINE; CHRONIC HEPATITIS C; COMPLICATION; GENETIC PREDISPOSITION; GENETICS; HEPG2 CELL LINE; LIVER NEOPLASMS; METABOLISM; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALCOHOLISM; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL LINE; CHONDROITIN SULFATE PROTEOGLYCANS; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HEP G2 CELLS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; LECTINS, C-TYPE; LIVER CIRRHOSIS, ALCOHOLIC; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; RNA, MESSENGER; YOUNG ADULT;

EID: 84932130955     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.06.006     Document Type: Article

References (41)

1. Rehm J, Shield KD, Gmel G, Rehm MX, Frick U. Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol 2013;23: 89-97.
2. Soyka M. Update alcohol dependence. Bremen: Unimed Verlag; 2013.
3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004;127: S35-S50.
4. Stickel F, Hampe J. Genetic determinants of alcoholic liver disease. Gut 2012;61: 150-159.
5. Guyot E, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, et al. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol 2013;58: 312-318.
6. Valenti L, Dongiovanni P, Ginanni Corradini S, Burza MA, Romeo S. PNPLA3 I148M variant and hepatocellular carcinoma: A common genetic variant for a rare disease. Dig Liver Dis 2013;45: 619-624.
7. Falleti E, Fabris C, Cmet S, Cussigh A, Bitetto D, Fontanini E, et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: Relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int 2011;31: 1137-1143.
8. Nischalke HD, Berger C, Luda C, Berg T, Muller T, Grunhage F, et al. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One 2011;6: E27087.
9. Stickel F, Buch S, Lau K, zu Schwabedissen HM, Berg T, Ridinger M, et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011;53: 86-95.
10. Trepo E, Guyot E, Ganne-Carrie N, Degre D, Gustot T, Franchimont D, et al. PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology 2012;55: 1307-1308.
11. Rauch U, Karthikeyan L, Maurel P, Margolis RU, Margolis RK. Cloning and primary structure of neurocan, a developmentally regulated, aggregating chondroitin sulfate proteoglycan of brain. J Biol Chem 1992;267: 19536-19547.
12. Rauch U, Feng K, Zhou XH. Neurocan: A brain chondroitin sulfate proteoglycan. Cell Mol Life Sci 2001;58: 1842-1856.
13. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008;40: 161-169.
14. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7: E1001324.
15. Gorden A, Yang R, Yerges-Armstrong LM, Ryan KA, Speliotes E, Borecki IB, et al. Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-Alcoholic fatty liver disease in morbid obesity. Hum Hered 2013;75: 34-43.
16. Hernaez R, McLean J, Lazo M, Brancati FL, Hirschhorn JN, Borecki IB, et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third national health and nutrition examination survey. Clin Gastroenterol Hepatol 2013;11: 1183-1190.
17. Zhou XH, Brakebusch C, Matthies H, Oohashi T, Hirsch E, Moser M, et al. Neurocan is dispensable for brain development. Mol Cell Biol 2001;21: 5970-5978.
18. Stickel F, Osterreicher CH, Halangk J, Berg T, Homann N, Hellerbrand C, et al. No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease. Alcohol Clin Exp Res 2008;32: 959-965.
19. Korner C, Riesner K, Kramer B, Eisenhardt M, Glassner A, Wolter F, et al. TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. BMC Cancer 2012;12: 85.
20. Mori R, Wang Q, Danenberg KD, Pinski JK, Danenberg PV. Both beta-Actin and GAPDH are useful reference genes for normalization of quantitative RTPCR in human FFPE tissue samples of prostate cancer. Prostate 2008;68: 1555-1560.
21. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7: 248-249.
22. Nahon P, Zucman-Rossi J. Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol 2012;57: 663-674.
23. Cabrera R, Nelson DR. Review article: The management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010;31: 461-476.
24. Cucchetti A, Cescon M, Trevisani F, Pinna AD. Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients. World J Gastroenterol 2012;18: 6398-6408.
25. Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl 2011;17: S6-S13.
26. EASL-EORTC clinical practice guidelines. Management of hepatocellular carcinoma. J Hepatol 2012;56: 908-943.
27. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011;53: 1020-1022.
28. Della Corte C, Colombo M. Surveillance for hepatocellular carcinoma. Semin Oncol 2012;39: 384-398.
29. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011;141: 141-149.
30. El-Serag HB. Hepatocellular carcinoma: An epidemiologic view. J Clin Gastroenterol 2002;35: S72-S78.
31. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379: 1245-1255.
32. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: A meta-Analysis of observational studies. Ann Intern Med 2013;158: 329-337.
33. Wong GL, Chan HL, Mak CH, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58: 1537-1547.
34. Nahon P, Sutton A, Rufat P, Ziol M, Thabut G, Schischmanoff PO, et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 2008;134: 102-110.
35. Charni F, Sutton A, Rufat P, Laguillier C, Mansouri A, Moreau R, et al. Chemokine RANTES promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virus-related cirrhosis. Cancer Epidemiol Biomarkers Prev 2011;20: 1439-1446.
36. Nahon P, Sutton A, Pessayre D, Rufat P, Degoul F, Ganne-Carrie N, et al. Genetic dimorphism in superoxide dismutase and susceptibility to alcoholic cirrhosis, hepatocellular carcinoma, and death. Clin Gastroenterol Hepatol 2005;3: 292-298.
37. Knobloch M, Braun SM, Zurkirchen L, von Schoultz C, Zamboni N, Arauzo-Bravo MJ, et al. Metabolic control of adult neural stem cell activity by Fasndependent lipogenesis. Nature 2013;493: 226-230.
38. MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceriderich lipoproteins independently of LDL receptor family members. J Clin Invest 2007;117: 153-164.
39. Olsson U, Egnell AC, Lee MR, Lunden GO, Lorentzon M, Salmivirta M, et al. Changes in matrix proteoglycans induced by insulin and fatty acids in hepatic cells may contribute to dyslipidemia of insulin resistance. Diabetes 2001;50: 2126-2132.
40. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-Alcoholic fatty liver disease: An emerging menace. J Hepatol 2012;56: 1384-1391.
41. Banerjee A, Ray RB, Ray R. Oncogenic potential of hepatitis C virus proteins. Viruses 2010;2: 2108-2133.